Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rosebank Industries abandons pursuit of ECI, shares slump

(Sharecast News) - Rosebank Industries slumped on Wednesday after the investment firm said it was abandoning its pursuit of US wire harness maker Electrical Components International "in light of the recent market volatility". The company announced last month that it was in talks with affiliates of Cerberus about a potential deal to buy ECI.

However, it said late on Tuesday that "despite receiving overwhelming support from both existing shareholders and new investors, in light of the recent market volatility, the company has decided it is not in its shareholders' best interests to proceed with the acquisition at the present time".

Chief executive Simon Peckham said: "We believe that ECI is a very good company with a high-quality management team and that it would have been a highly successful first investment for Rosebank.

"Despite a successful equity fundraising process, it disappointingly became clear that the current volatility in the political and equity markets meant it was not, at this moment, in our investors' best interests to proceed. We would like to thank investors for their continuing strong support."

At 1025 GMT, the shares were down 15% at 630p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.